azteckingslot|大行评级｜里昂：上调信达生物目标价至58.1港元维持“买入”评级

Business 2024年05月06日 13:59 7 editor

Lyon published a research report stating that Cinda Biotech's product sales in the first quarter of fiscal year 2024 increased by 60% year-on-year, exceeding expectations. Coupled with innovative drug policies in recent monthsazteckingslotDriven by, the bank remains confident about the company's sales prospects in the coming quarters. Lyon therefore set Cinda Biotech's target price from 57azteckingslotHK$..5 was upgraded to HK$58.1, maintaining the "Buy" rating.